CHICAGO - Tempus AI, Inc. (NASDAQ:TEM) announced today the launch of a digital pathology IMS Open-Source Consortium with Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center as founding academic members, according to a press release statement.
The consortium aims to develop an open-source digital pathology platform and viewer. The initiative comes as Tempus, valued at $8.9 billion, continues its aggressive expansion with revenue growth of nearly 70% over the last twelve months, though InvestingPro data shows the company remains unprofitable. According to InvestingPro, the stock currently trades above its Fair Value, placing it among overvalued healthcare technology companies. Investors can access a comprehensive Pro Research Report on TEM, one of 1,400+ available reports that transform complex financial data into actionable intelligence. Tempus will open source the existing Paige Image Management System, including the slide viewer FullFocus, case management solution FullFolio, and AI orchestration and integration modules.
Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center will contribute to defining the vision, governance, and strategic direction of the open-source ecosystem. The consortium is expected to expand its membership over time.
"Digital pathology lacks opensource and openaccess clinical-grade solutions for on-prem/cloud slide viewing, case management, and AI deployment," said Saad Nadeem, Associate Attending Computer Scientist at Memorial Sloan Kettering Cancer Center.
Chen Liu, Chief of Pathology at Yale New Haven Hospital, said the institution is excited to collaborate with leading academic and industry partners to build an open, scalable, and interoperable digital pathology ecosystem.
The consortium operates independently of Tempus’ current digital pathology commercial offering. Organizations interested in joining can contact the consortium at IMSConsortium@tempus.com.
Tempus is a licensing partner with Memorial Sloan Kettering Cancer Center and provides research funding to the institution for certain activities.
In other recent news, Tempus AI, Inc. has announced several significant developments. The company received FDA approval for its xT CDx next-generation sequencing platform, allowing it to operate as a tumor-only test without needing a matched normal sample. This makes Tempus the first laboratory to achieve FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling. Additionally, Tempus presented results from its multimodal foundation models at the 2026 American Society of Clinical Oncology Annual Meeting, showcasing its advanced transformer-based model trained on extensive clinical data.
Analyst coverage has also been active, with Wolfe Research initiating coverage on Tempus AI with a Peerperform rating, assigning a fair value range of $40 to $65 per share. This evaluation considers a long-term discounted cash flow model for various business segments. In contrast, Canaccord Genuity reiterated a Buy rating and set a price target of $80 per share following Tempus’s investor day, highlighting the company’s growth potential. These developments underscore Tempus AI’s strategic advancements and analyst interest.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for TEM plus thousands of other stocks and find your next hidden gem with massive upside.